Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Teva Announces Strategic Collaboration with Klinge Biopharma and Formycon for Commercializing Biosimilar Candidate to Eylea in Europe and Israel
Jan 13, 2025
Contract Type
partnership
Tel AvivManufacturingBiotechnologyHealth CareTherapeuticsPharmaceutical
Description
Teva Pharmaceuticals International GmbH has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea (aflibercept) in Europe, excluding Italy, and in Israel. This collaboration aims to leverage Teva's commercial experience, distribution network, and sales and marketing reach across Europe with Formycon's capabilities in biosimilar medicine development.
Company Information
Company
Teva Pharmaceutical Industries Ltd
Location
Tel Aviv, Tel Aviv District, Israel
About
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of people worldwide. With a focus on innovative medicines, especially in areas of central nervous system, pain, and respiratory therapies, Teva is dedicated to improving health and increasing access to medicines around the world.